openPR Logo
Press release

In Depth Research on

10-04-2017 06:51 AM CET | Health & Medicine

Press release from: Kuick Resarch

“Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015” Report Highlight:

* Nomenclature & Classification of CD Antigens
* Mechanism of CD Antigen Cancer Therapeutics
* Cancer CD Antigen Therapy Market Overview
* Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
* Cancer CD Antigen Inhibitors Clinical Pipeline: 207 Drugs
* Marketed Cancer CD Antigen Inhibitors: 27 Drugs
* Majority of Cancer CD Antigen Inhibitors in Preclinical Phase: 70 Drugs
* Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 44 Drugs
* Cancer CD Antigens Clinical Pipeline is Represented in 52 Graphs & Charts

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Cancer-CD-Antigen-Inhibitors-Market-&-Pipeline-Insight2015.php

Table of Contents

1. Introduction to CD Antigens

2. Nomenclature & Classification of CD Antigens

3. Mechanism of CD Antigen Cancer Therapeutics

4. Cancer CD Antigen Therapy Market Overview
4.1 Current Scenario
4.2 Cancer CD Antigen Inhibitors Pipeline Overview

5. CD Antigen Cancer Market Dynamics
5.1 Favorable Market Parameters
5.2 Commercialization Challenges

6. CD Antigen Cancer Therapeutics Future Prospects

7. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
7.1 Phase-I/II

8. Cancer CD3 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
8.1 Preclinical till Phase-II

9. Cancer CD4 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
9.1 Phase-II

10. Cancer CD9 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
10.1 Preclinical

11. Cancer CD11 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
11.1 Preclinical

12. Cancer CD19 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
12.1 Phase-I till Phase-II

13. Cancer CD20 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
13.1 Research till Phase-III
13.2 Marketed CD20 Antigen Inhibitors Drug Clinical Insight

14. Cancer CD22 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
14.1 Phase-II till Phase-III

15. Cancer CD26 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
15.1 Preclinical till Phase-I/II

16. Cancer CD27 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
16.1 Research till Phase-I/II

17. Cancer CD28 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
17.1 Preclinical

18. Cancer CD29 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
18.1 Preclinical

19. Cancer CD33 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
19.1 Phase-I till Phase-I/II
19.2 Marketed CD33 Antigen Inhibitors Drug Clinical Insight

20. Cancer CD37 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
20.1 Phase-I till Phase-II

21. Cancer CD38 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
21.1 Research till Preregistration

22. Cancer CD40 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
22.1 Phase-I

23. Cancer CD44 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
23.1 Preclinical

24. Cancer CD45 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
24.1 Preclinical till Phase-II

25. Cancer CD47 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
25.1 Preclinical till Phase-I

26. Cancer CD52 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
26.1 Research till Preclinical
26.2 Marketed CD52 Antigen Inhibitors Drug Clinical Insight

27. Cancer CD55 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
27.1 Preclinical till Phase-II

28. Cancer CD56 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
28.1 Preclinical till Phase-II

29. Cancer CD66 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
29.1 Preclinical till Phase-II

30. Cancer CD70 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
30.1 Phase-I

31. Cancer CD74 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
31.1 Preclinical till Phase-I/II

32. Cancer CD80 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
32.1 Preclinical till Phase-II

33. Cancer CD95 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
33.1 Preclinical

34. Cancer CD98 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
34.1 Phase-I

35. Cancer CD100 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
35.1 Phase-I

36. Cancer CD117 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
36.1 Preclinical till Phase-III
36.2 Marketed CD117 Antigen Inhibitors Drug Clinical Insight

37. Cancer CD135 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
37.1 Preclinical till Phase-III
37.2 Marketed CD135 Antigen Inhibitors Drug Clinical Insight

38. Cancer CD137 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
38.1 Preclinical

39. Cancer CD152 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
39.1 Marketed CD152 Antigen Inhibitors Drug Clinical Insight

40. Cancer CD200 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
40.1 Preclinical

41. Cancer CD223 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
41.1 Research till Phase-I

42. Cancer CD227 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
42.1 Phase-I till Phase-II

43. Cancer CD246 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
43.1 Preclinical till Phase-II
43.2 Marketed CD246 Antigen Inhibitors Drug Clinical Insight

44. Cancer CD248 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
44.1 Phase-II

45. Cancer CD274 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
45.1 Research till Phase-III
45.2 Marketed CD274 Antigen Inhibitors Drug Clinical Insight

46. Cancer CD276 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
46.1 Phase-I

47. Cancer CD279 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
47.1 Phase-I till Phase-II
47.2 Marketed CD279 Antigen Inhibitors Drug Clinical Insight

48. Multiple Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
48.1 Preclinical till Phase-III
48.2 Marketed Multiple CD Antigen Inhibitors Drug Clinical Insight

49. Discontinued & Suspended Cancer CD Antigen Inhibitors Drug Clinical Insight
49.1 No Development Reported
49.2 Discontinued
49.3 Market Withdrawal
49.4 Suspended

50. Competitive Landscape
50.1 Alexion Pharmaceuticals
50.2 ARIAD Pharmaceuticals
50.3 AryoGen Biopharma
50.4 AXXO
50.5 Bayer HealthCare
50.6 Biocad
50.7 Biogen
50.8 Biotecnol Inc.
50.9 Bristol-Myers Squibb
50.10 Chugai Pharmaceutical
50.11 Dr Reddy’s Laboratories
50.12 Eisai Co Ltd
50.13 Emergent BioSolutions
50.14 Genmab
50.15 ImmunoGen
50.16 Intas Biopharmaceuticals
50.17 MacroGenics
50.18 MedImmune
50.19 Merck
50.20 Novartis
50.21 Ono Pharmaceutical
50.22 Onyx Pharmaceuticals
50.23 Pfizer
50.24 PROBIOMED
50.25 Roche
50.26 UCB
50.27 Xencor

Figure 1-1: Functions of CD Antigens
Figure 1-2: Properties of CD Antigens
Figure 2-1: Types of WBC
Figure 2-2: Classification of CD Antigens
Figure 3-1: Important Features of CD Antigens
Figure 3-2: Mechanism of Rituximab
Figure 3-3: Mechanism of Brentuximab Vedotin
Figure 3-4: Mechanism of Blinatumomab
Figure 3-5: Mechanism of Ibritumomab Tiuxetan
Figure 3-6: Mechanism of Tositumomab Iodine 131
Figure 3-7: Mechanism of Catumaxomab
Figure 4-1: Cancer CD Antigen Inhibitors Pipeline by Phase (%), 2015
Figure 4-2: Cancer CD Antigen Inhibitors Pipeline by Phase (Number), 2015
Figure 4-3: Cancer CD3 Antigen Pipeline by Phase (%), 2015
Figure 4-4: Cancer CD3 Antigen Pipeline by Phase (Number), 2015
Figure 4-5: Cancer CD19 Antigen Pipeline by Phase (%), 2015
Figure 4-6: Cancer CD19 Antigen Pipeline by Phase (Number), 2015
Figure 4-7: Cancer CD20 Antigen Pipeline by Phase (%), 2015
Figure 4-8: Cancer CD20 Antigen Pipeline by Phase (Number), 2015
Figure 4-9: Cancer CD22 Antigen Pipeline by Phase (%), 2015
Figure 4-10: Cancer CD22 Antigen Pipeline by Phase (Number), 2015
Figure 4-11: Cancer CD26 Antigen Pipeline by Phase (%), 2015
Figure 4-12: Cancer CD26 Antigen Pipeline by Phase (Number), 2015
Figure 4-13: Cancer CD27 Antigen Pipeline by Phase (%), 2015
Figure 4-14: Cancer CD27 Antigen Pipeline by Phase (Number), 2015
Figure 4-15: Cancer CD33 Antigen Pipeline by Phase (%), 2015
Figure 4-16: Cancer CD33 Antigen Pipeline by Phase (Number), 2015
Figure 4-17: Cancer CD38 Antigen Pipeline by Phase (%), 2015
Figure 4-18: Cancer CD38 Antigen Pipeline by Phase (Number), 2015
Figure 4-19: Cancer CD45 Antigen Pipeline by Phase (%), 2015
Figure 4-20: Cancer CD45 Antigen Pipeline by Phase (Number), 2015
Figure 4-21: Cancer CD47 Antigen Pipeline by Phase (%), 2015
Figure 4-22: Cancer CD47 Antigen Pipeline by Phase (Number), 2015
Figure 4-23: Cancer CD52 Antigen Pipeline by Phase (%), 2015
Figure 4-24: Cancer CD52 Antigen Pipeline by Phase (Number), 2015
Figure 4-25: Cancer CD55 Antigen Pipeline by Phase (%), 2015
Figure 4-26: Cancer CD55 Antigen Pipeline by Phase (Number), 2015
Figure 4-27: Cancer CD56 Antigen Pipeline by Phase (%), 2015
Figure 4-28: Cancer CD56 Antigen Pipeline by Phase (Number), 2015
Figure 4-29: Cancer CD66 Antigen Pipeline by Phase (%), 2015
Figure 4-30: Cancer CD66 Antigen Pipeline by Phase (Number), 2015
Figure 4-31: Cancer CD74 Antigen Pipeline by Phase (%), 2015
Figure 4-32: Cancer CD74 Antigen Pipeline by Phase (Number), 2015
Figure 4-33: Cancer CD80 Antigen Pipeline by Phase (%), 2015
Figure 4-34: Cancer CD80 Antigen Pipeline by Phase (Number), 2015
Figure 4-35: Cancer CD117 Antigen Pipeline by Phase (%), 2015
Figure 4-36: Cancer CD117 Antigen Pipeline by Phase (Number), 2015
Figure 4-37: Cancer CD135 Antigen Pipeline by Phase (%), 2015
Figure 4-38: Cancer CD135 Antigen Pipeline by Phase (Number), 2015
Figure 4-39: Cancer CD223 Antigen Pipeline by Phase (%), 2015
Figure 4-40: Cancer CD223 Antigen Pipeline by Phase (Number), 2015
Figure 4-41: Cancer CD227 Antigen Pipeline by Phase (%), 2015
Figure 4-42: Cancer CD227 Antigen Pipeline by Phase (Number), 2015
Figure 4-43: Cancer CD246 Antigen Pipeline by Phase (%), 2015
Figure 4-44: Cancer CD246 Antigen Pipeline by Phase (Number), 2015
Figure 4-45: Multiple Cancer CD Antigen Pipeline by Phase (%), 2015
Figure 4-46: Multiple Cancer CD Antigen Pipeline by Phase (Number), 2015
Figure 4-47: Cancer CD Antigen Inhibitors No Development Reported Pipeline by Phase (%), 2015
Figure 4-48: Cancer CD Antigen Inhibitors No Development Reported Pipeline by Phase (Number), 2015
Figure 4-49: Cancer CD Antigen Inhibitors Discontinued Pipeline by Phase (%), 2015
Figure 4-50: Cancer CD Antigen Inhibitors Discontinued Pipeline by Phase (Number), 2015
Figure 4-51: Cancer CD Antigen Inhibitors Suspended Pipeline by Phase (%), 2015
Figure 4-52: Cancer CD Antigen Inhibitors Suspended Pipeline by Phase (Number), 2015
Figure 5-1: Favorable Market Features
Figure 5-2: Cancer CD Antigen Inhibitors Commercialization Challenges

List of Tables
Table 5-1: Different CD Antigens used for Hematological Malignancies

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release In Depth Research on here

News-ID: 753548 • Views: 392

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Phase

2026 Global Pharmacovigilance Market Growth Analysis by Clinical Trials Like Pre …
Global Pharmacovigilance Market 2018 report includes extensive Market analysis and industry landscape along with SWOT analysis and PESTEL analysis of the important vendors. The analysis is conducted with a blend of secondary and primary advice for inputs from participants in the industry. Pharmacovigilance industry report covers the prospects of Women’S Health P oducts in the forecast period of 2018-2026 and the scenario. Growing prevalence of adverse reactions caused by drugs, has
Reverse Phase Columns (Professional Survey Report 2017)
"Global Reverse Phase Columns Market Professional Survey Report 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- '
MAAT Inaugurates Versatile Phase Shifter
Company announces release of a digital recreation of Roger Schult’s analog hardware MAAT Incorporated, a manufacturer of exceptional performance professional audio solutions, today announced the release of RSPhaseShifter version 1.0, a digital implementation of the Roger Schult/German Audio Lab’s Phase Shifter 500 Series W2324 hardware. The cross–platform plug–in creates a high quality, phase shifted version of a monaural or stereo input. Available in formats for all major DAWs (Digital Audio Workstations), RSPhaseShifter
Pre-Registration, Filing Rejected/Withdrawn, Phase Iii, Phase Ii, Phase I, Precl …
"Migraine - Pipeline Review, H2 2016" The Report covers current Market Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. Description- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine Pipeline Review, H2 2016, provides an overview of the Migraine (Central Nervous System) pipeline landscape. Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of
Daisho Blacksmith completes successful Beta Test Phase
Huge support from users by brisk participation at beta test • Sync release could be further optimized • Official sync release shortly available as download Munich, february 23rd 2011. The beta test for the new version of the personal information management software DAISHO was successfully completed. Daisho Blacksmith, developer of the PIM tool, would like to thank the numerous testers which have actively contributed to the enhancement of DAISHO through their dedicated testing.
Epsilon Award 2008 - Nomination phase has started
The Epsilon Award is a combination of Excellency, craftsmanship and visionary ability. These are characteristics of an outstanding programmer and a piece of true software art. And you can now send your application for nomination for this prestigious award of our software industry. Please read all details and find the relevant signup link www.euroconference.org/Epsilon_Vote.htm on the webportal of the European Software Conference 2008, taking place in Berlin on November 8